Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile POLE inact mut
Therapy unspecified immune checkpoint inhibitor
Indication/Tumor Type colorectal cancer
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
POLE inact mut colorectal cancer predicted - sensitive unspecified immune checkpoint inhibitor Clinical Study - Cohort Actionable In a clinical study, immunotherapy resulted in improved clinical benefit in patients with metastatic colorectal cancer harboring POLE inactivating mutations (n=7, 3 complete responses, 3 partial responses, 1 stable disease (SD)) and durable response (remained on therapy with median follow up of 36 months) compared to microsatellite stable (MSS) patients harboring non-loss-of-function POLE mutations (n=7, 2 SD; median progression-free survival 3.6 months, p<0.0003) (Ann Oncol (2023) 34 (suppl_2): S448-S449). detail...
PubMed Id Reference Title Details
631P Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy Full reference...